Bioscience advocates call for biosimilar support
Delaware BioScience Association President Bob Dayton and BIO President and CEO Jim Greenwood in this letter to the editor call on Delaware's lawmakers to protect consumer safety and ensure innovation of biosimilars as Congress works on health care reform legislation. Creating an avenue for regulatory approval will ensure biosimilars "are tested for safety while expanding access, lowering costs through expanded competition and providing incentives for biotech companies to continue innovating," they write.
delawareonline | 11/02
This story published in BIO SmartBrief on 11/03/2009
BIO, Wis. group criticize proposed patent exemption of genetic tests
Monday, October 19, 2009
Cornelius: Bristol-Myers can afford more acquisitions
Friday, October 23, 2009
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|